

[Hydroxycarbamide \(hydroxyurea\)](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01XX05](#)

EMLc

Indication

Chronic myeloid leukaemia, not elsewhere classified ICD11 code: [2B33.2](#)

INN

Hydroxycarbamide

Medicine type

Chemical agent

List type

Complementary

Formulations

**Oral > Solid > dosage form:** 200 mg ; 300 mg ; 400 mg ; 500 mg ; 1 g ; 100 mg (EMLc)

EML status history

First added in 2009 ([TRS 958](#))

Changed in 2015 ([TRS 994](#))

Changed in 2019 ([TRS 1021](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Hydroxycarbamide \(hydroxyurea\)](#)

DrugBank

[Hydroxycarbamide \(Hydroxyurea\)](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the deletion of hydroxycarbamide 250 mg solid oral dosage from the EML and EMLc, and the addition of hydroxycarbamide 100 mg solid oral dosage form to the EMLc.